Generic Pediatric Labeling, ANDA Review Times To Be Addressed By OGD
This article was originally published in The Tan Sheet
Executive Summary
Situations in which different private label manufacturers are first to make paragraph IV certifications against separate patents covering the same drug is an issue of increasing importance for FDA's Office of Generic Drugs